Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis

Nanomedicine

Volumn 9, Issue 6, 2014, Pages 789-801

  Duan, Juanli ^a   Dong, Jinlai ^a   Zhang, Tiantian ^a   Su, Zhenyi ^b   Ding, Jie ^b   Zhang, Yu ^a   Mao, Xiaohua ^a,b  

^a SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

IL 2 IL 15Rb; macrophage; nanoparticle; rheumatoid arthritis; siRN

Indexed keywords

INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR; NANOCARRIER; POLYETHYLENEIMINE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; FERRIC ION; FERRIC OXIDE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; MAGNETITE NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EXPERIMENTAL ARTHRITIS; GENE SILENCING; IN VITRO STUDY; MACROPHAGE; MAGNETIC FIELD; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; RNA STABILITY; SINGLE DRUG DOSE; SYNTHESIS; T LYMPHOCYTE; TISSUE DISTRIBUTION; ANIMAL; ARTHRITIS, EXPERIMENTAL; BOVINAE; CELL CULTURE; CHEMISTRY; GENETICS; RNA INTERFERENCE; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CATTLE; CELLS, CULTURED; DRUG CARRIERS; FERRIC COMPOUNDS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MAGNETITE NANOPARTICLES; MALE; POLYETHYLENEIMINE; RATS; RATS, WISTAR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84903782299     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.217     Document Type: Article

References (30)

1. Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9(9), 703-718 (2010).
2. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr. Opin. Rheumatol. 23(3), 245-251 (2011).
3. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology 51(Suppl. 6), vi28-vi36 (2012).
4. Scott D. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin. Pharmacol. Ther. 91(1), 30-43 (2011).
5. Liu G, Xie J, Zhang F et al. N-alkyl-PEI-functionalized iron oxide nanoclusters for efficient siRNA delivery. Small 7(19), 2742-2749 (2011).
6. Zhang H, Lee M-Y, Hogg MG, Dordick JS, Sharfstein ST. Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles. ACS Nano 4(8), 4733-4743 (2010).
7. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases:vascular rheumatology. Arthritis Res. Ther. 10(5), 224 (2008).
8. Kinne RW, Stuhlmller B, Burmester G-R. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res. Ther. 9(6), 224 (2007).
9. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 19(3), 289-295 (2007). (Pubitemid 46597469)
10. Brennan FM, Mcinnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118(11), 3537 (2008).
11. Mcinnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. 4(4), 392-397 (2004). (Pubitemid 38987067)
12. Zhang T, Bai X, Mao X. Systemic delivery of small interfering RNA targeting the interleukin-2/15 receptor b chain prevents disease progression in experimental arthritis. PLoS ONE 8(11), e78619 (2013).
13. Wang CY, Hong JM, Chen G, Zhang Y, Gu N. Facile method to synthesize oleic acid-capped magnetite nanoparticles. Chinese Chem. Lett. 21(2), 179-182 (2010).
14. Wu Y, Song M, Xin Z et al. Ultra-small particles of iron oxide as peroxidase for immunohistochemical detection. Nanotechnology 22(22), 225703 (2011).
15. Wang D, Deng X, Leng X, Mao X. Interleukin-15 receptor-directed immunotoxins atteunuate disease severity in rat adjuvant arthritis. Mol. Immunol. 47(7), 1535-1543 (2010).
16. Cole AJ, David AE, Wang J, Galbán CJ, Yang VC. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials 32(26), 6291-6301 (2011).
17. Xia T, Kovochich M, Liong M et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3(10), 3273-3286 (2009).
18. Courties G, Seiffart V, Presumey J et al. In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 116(18), 3505-3516 (2010).
19. Mitragotri S, Yoo J-W. Designing micro- and nano-particles for treating rheumatoid arthritis. Arch. Pharm. Res. 34(11), 1887-1897 (2011).
20. Khaja FA, Koo O, Onyuksel H. Nanomedicines for inflammatory diseases. Methods Enzymol. 508, 355-375 (2012).
21. Butoescu N, Seemayer CA, Foti M, Jordan O, Doelker E. Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis. Biomaterials 30(9), 1772-1780 (2009).
22. Butoescu N, Seemayer C, Palmer G et al. Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice. Arthritis Res. Ther. 11(3), R72 (2009).
23. Scheinman RI, Trivedi R, Vermillion S, Kompella UB. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond.) 6(10), 1669-1682 (2011).
24. Khoury M, Louis-Plence P, Escriou V et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor a in experimental arthritis. Arthritis Rheum. 54(6), 1867-1877 (2006). (Pubitemid 43877936)
25. Khoury M, Escriou V, Courties G et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 58(8), 2356-2367 (2008).
26. Apparailly F, Jorgensen C. siRNA-based therapeutic approaches for rheumatic diseases. Nat. Rev. Rheumatol. 9(1), 56-62 (2013).
27. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 97(1), 14-32 (2001). (Pubitemid 32061238)
28. Kurreeman F, Daha N, Chang M et al. Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Ann. Rheum. Dis. 68(11), 1789-1790 (2009).
29. Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo- Repo M. Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. Ann. Rheum. Dis. 65(1), 26-29 (2006). (Pubitemid 41815635)
30. Mcinnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-A production in rheumatoid arthritis. Nat. Med. 3(2), 189-195 (1997). (Pubitemid 27064704)